Allergan PLC. (AGN) Stake Held by Tributary Capital Management LLC, Report finds

Allergan PLC. (AGN) Stake Held by Tributary Capital Management LLC, Report finds

Tributary Capital Management LLC continued to hold its position in shares of Allergan PLC. (NYSE:AGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,810 shares of the company’s stock at the end of the third quarter. Tributary Capital Management LLC’s holdings in Allergan PLC. were worth $877,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. LS Investment Advisors LLC boosted its position in shares of Allergan PLC. by 17.1% in the second quarter. LS Investment Advisors LLC now owns 4,341 shares of the company’s stock worth $1,003,000 after buying an additional 634 shares during the last quarter. Huntington National Bank bought a new position in Allergan PLC. during the second quarter valued at about $6,500,000. Whittier Trust Co. boosted its position in Allergan PLC. by 7.3% in the second quarter. Whittier Trust Co. now owns 1,446 shares of the company’s stock valued at $334,000 after buying an additional 98 shares in the last quarter. Atlas Brown Inc. boosted its position in Allergan PLC. by 56.0% in the second quarter. Atlas Brown Inc. now owns 3,209 shares of the company’s stock valued at $742,000 after buying an additional 1,152 shares in the last quarter. Finally, Essex Financial Services Inc. boosted its position in Allergan PLC. by 25.8% in the second quarter. Essex Financial Services Inc. now owns 1,580 shares of the company’s stock valued at $365,000 after buying an additional 324 shares in the last quarter. Institutional investors own 87.69% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded up 3.68% during mid-day trading on Wednesday, hitting $241.17. The stock had a trading volume of 6,587,224 shares. The company has a market cap of $90.46 billion, a PE ratio of 6.76 and a beta of 1.07. Allergan PLC. has a one year low of $184.50 and a one year high of $301.32. The firm’s 50-day moving average price is $215.91 and its 200 day moving average price is $223.07.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, February 8th. The company reported $3.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.73 by $0.17. Allergan PLC. had a return on equity of 7.26% and a net margin of 93.74%. The firm earned $3.86 billion during the quarter, compared to analysts’ expectations of $3.77 billion. During the same period in the previous year, the business earned $3.41 earnings per share. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. On average, equities research analysts anticipate that Allergan PLC. will post $13.39 EPS for the current year.

Several equities analysts have issued reports on AGN shares. Mizuho lowered their target price on shares of Allergan PLC. from $305.00 to $299.00 and set a “buy” rating on the stock in a research note on Tuesday, October 11th. Deutsche Bank AG set a $278.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Saturday, October 15th. Barclays PLC restated an “equal weight” rating and set a $250.00 target price on shares of Allergan PLC. in a research note on Monday, October 31st. Credit Suisse Group restated an “outperform” rating and set a $329.00 target price on shares of Allergan PLC. in a research note on Thursday, November 3rd. Finally, Royal Bank Of Canada lowered their target price on shares of Allergan PLC. from $300.00 to $279.00 and set an “outperform” rating on the stock in a research note on Thursday, November 3rd. Eight investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus price target of $271.49.

In related news, CFO Maria Teresa Hilado bought 1,422 shares of the company’s stock in a transaction on Friday, November 11th. The stock was bought at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the acquisition, the chief financial officer now directly owns 12,659 shares in the company, valued at $2,666,491.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Brent L. Saunders bought 5,250 shares of the company’s stock in a transaction on Monday, November 21st. The stock was bought at an average price of $189.13 per share, with a total value of $992,932.50. The disclosure for this purchase can be found here. 0.27% of the stock is currently owned by insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Related posts

Leave a Comment

Allergan PLC. (AGN) Stake Held by Tributary Capital Management LLC

Allergan PLC. (AGN) Stake Held by Tributary Capital Management LLC

Tributary Capital Management LLC continued to hold its position in shares of Allergan PLC. (NYSE:AGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,810 shares of the company’s stock at the end of the third quarter. Tributary Capital Management LLC’s holdings in Allergan PLC. were worth $877,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. LS Investment Advisors LLC boosted its position in shares of Allergan PLC. by 17.1% in the second quarter. LS Investment Advisors LLC now owns 4,341 shares of the company’s stock worth $1,003,000 after buying an additional 634 shares during the last quarter. Huntington National Bank bought a new position in Allergan PLC. during the second quarter valued at about $6,500,000. Whittier Trust Co. boosted its position in Allergan PLC. by 7.3% in the second quarter. Whittier Trust Co. now owns 1,446 shares of the company’s stock valued at $334,000 after buying an additional 98 shares in the last quarter. Atlas Brown Inc. boosted its position in Allergan PLC. by 56.0% in the second quarter. Atlas Brown Inc. now owns 3,209 shares of the company’s stock valued at $742,000 after buying an additional 1,152 shares in the last quarter. Finally, Essex Financial Services Inc. boosted its position in Allergan PLC. by 25.8% in the second quarter. Essex Financial Services Inc. now owns 1,580 shares of the company’s stock valued at $365,000 after buying an additional 324 shares in the last quarter. Institutional investors own 87.69% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded up 3.68% during mid-day trading on Wednesday, hitting $241.17. The stock had a trading volume of 6,587,224 shares. The company has a market cap of $90.46 billion, a PE ratio of 6.76 and a beta of 1.07. Allergan PLC. has a one year low of $184.50 and a one year high of $301.32. The firm’s 50-day moving average price is $215.91 and its 200 day moving average price is $223.07.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, February 8th. The company reported $3.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.73 by $0.17. Allergan PLC. had a return on equity of 7.26% and a net margin of 93.74%. The firm earned $3.86 billion during the quarter, compared to analysts’ expectations of $3.77 billion. During the same period in the previous year, the business earned $3.41 earnings per share. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. On average, equities research analysts anticipate that Allergan PLC. will post $13.39 EPS for the current year.

Several equities analysts have issued reports on AGN shares. Mizuho lowered their target price on shares of Allergan PLC. from $305.00 to $299.00 and set a “buy” rating on the stock in a research note on Tuesday, October 11th. Deutsche Bank AG set a $278.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Saturday, October 15th. Barclays PLC restated an “equal weight” rating and set a $250.00 target price on shares of Allergan PLC. in a research note on Monday, October 31st. Credit Suisse Group restated an “outperform” rating and set a $329.00 target price on shares of Allergan PLC. in a research note on Thursday, November 3rd. Finally, Royal Bank Of Canada lowered their target price on shares of Allergan PLC. from $300.00 to $279.00 and set an “outperform” rating on the stock in a research note on Thursday, November 3rd. Eight investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus price target of $271.49.

In related news, CFO Maria Teresa Hilado bought 1,422 shares of the company’s stock in a transaction on Friday, November 11th. The stock was bought at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the acquisition, the chief financial officer now directly owns 12,659 shares in the company, valued at $2,666,491.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Brent L. Saunders bought 5,250 shares of the company’s stock in a transaction on Monday, November 21st. The stock was bought at an average price of $189.13 per share, with a total value of $992,932.50. The disclosure for this purchase can be found here. 0.27% of the stock is currently owned by insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Related posts

Leave a Comment